|424B5||prospectus filed pursuant to rule 424||Jun 18, 2013||297.5 KB|
|8-K||current report||Jun 18, 2013||336.4 KB|
|SC 13G/A||amended statement of beneficial ownership||Jun 10, 2013||24.6 KB|
|8-K||current report||May 29, 2013||54.1 KB|
|4||smith, david v||May 28, 2013||26.9 KB|
|4||parker, h stewart||May 28, 2013||26.9 KB|
|4||mattingly, martin a||May 28, 2013||26.9 KB|
|4||goldstein, jack||May 28, 2013||26.9 KB|
|4||clendeninn, neil james||May 28, 2013||26.9 KB|
|10-Q||quarterly report||May 2, 2013||428.7 KB|
|8-K||current report||May 2, 2013||61.3 KB|
|DEF 14A||definitive proxy statement||Apr 22, 2013||682.9 KB|
|PRE 14A||preliminary proxy statement||Apr 3, 2013||682.4 KB|
|4||wyrick, susan d.||Mar 14, 2013||26.7 KB|
|4||jacobs, cindy||Mar 14, 2013||29.1 KB|
|4||cormack, scott daniel||Mar 14, 2013||29.9 KB|
|10-K||annual report||Mar 7, 2013||1.0 MB|
|8-K||current report||Mar 7, 2013||65.6 KB|
|SC 13G/A||amended statement of beneficial ownership||Feb 14, 2013||51.3 KB|
|SC 13G/A||amended statement of beneficial ownership||Feb 14, 2013||25.1 KB|
© 2004-2011 OncoGenex Pharmaceuticals Inc. All rights reserved.
OncoGenex product candidates are investigational drugs for use only in approved clinical trials.
OncoGenex Pharmaceuticals is a drug discovery and development company uniquely focused on the challenge of cancer treatment resistance.
OncoGenex is uniquely focused on the challenge of cancer treatment resistance. We currently have several on-going clinical trials that may be of interest to you.
OncoGenex focuses on diverse molecular entities that target mechanisms of resistance and that have the potential to re-define treatment paradigms in a variety of cancers.